Browsing by Author "Bug, G."
Now showing 1 - 16 of 16
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings454 next generation sequencing identifies TP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q): Results from the German Le-Mon-5 trial(Karger, 2013)
; - Some of the metrics are blocked by yourconsent settingsCombined FISH- and SNP-array-analyses of circulating CD34+cells of MDS patients(Karger, 2012)
; ; ; - Some of the metrics are blocked by yourconsent settingsCytogenetic diagnostics of CD34+peripheral blood cells in MDS: Results from the multicenter German prospective diagnostic CD34+FISH study(Karger, 2012)
; ; ; - Some of the metrics are blocked by yourconsent settingsCytogenetic monitoring from peripheral blood in patients with myelodysplastic syndrome: First results from the German LEMON-5 trial(Karger, 2016)
; ; ; ; ; - Some of the metrics are blocked by yourconsent settingsData from the German-Austrian-Suisse MDS registry (D-A-CH MDS registry)(Karger, 2011)
; ; - Some of the metrics are blocked by yourconsent settingsFISH analyses on circulating CD34+cells in MDS: Results of the ongoing multicentric prospective diagnostic study with special focus on karyotype evolution and the correlation with conventional bone marrow diagnostics(Karger, 2010)
; ; - Some of the metrics are blocked by yourconsent settingsImpact of TP53 mutations on the clinical course in patients with MDS and isolated deletion 5(q) treated with Lenalidomid: results from the prospective Le-Mon-5 trial(Karger, 2014)
; ; - Some of the metrics are blocked by yourconsent settingsKaryotype evolution detected in CD34+peripheral blood cells of MDS patients: First results of the ongoing prospective German diagnostic study(Pergamon-elsevier Science Ltd, 2013)
; - Some of the metrics are blocked by yourconsent settingsKaryotype evolution in MDS patients detected by CD34+PB - FISH first results of the ongoing prospective multi-center German diagnostic study(Karger, 2013)
; ; ; - Some of the metrics are blocked by yourconsent settingsPrevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)(Nature Publishing Group, 2016)
; ; ; - Some of the metrics are blocked by yourconsent settingsResponse and progression rate of patients with primary MDS and isolated del(5q), IPSS low/int1 under treatment with lenalidomide(Pergamon-elsevier Science Ltd, 2013)
- Some of the metrics are blocked by yourconsent settingsRESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q)(Pergamon-elsevier Science Ltd, 2015)
; - Some of the metrics are blocked by yourconsent settingsSequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study(Nature Publishing Group, 2013)
; ; ; Wermke, Martin - Some of the metrics are blocked by yourconsent settingsSyk and Btk induce cell survival and proliferation in AML cells by activating distinct signaling pathways and transcriptional programs(Karger, 2014)
; ; ; ; Serve, Hubert - Some of the metrics are blocked by yourconsent settingsThe IPSS-R has prognostic impact in untreated patients with MDS del(5q)(2018)
; ; - Some of the metrics are blocked by yourconsent settingsTP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q) treated with lenalidomide: Results from the German Le-Mon-5 trial(Pergamon-elsevier Science Ltd, 2013)
;